Condition
Lymphoma, Non-Hodgkin's, Adult
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting2
Withdrawn1
Unknown1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06510361Phase 2Recruiting
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06343311Phase 1Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT03417765Phase 1WithdrawnPrimary
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
NCT05078840UnknownPrimary
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
NCT05979857Early Phase 1Not Yet RecruitingPrimary
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Showing all 5 trials